O15 Assessment of distal penetration, radiopacity, and biological safety response of NeoCast(TM), a unique solvent-free, non-adhesive embolic material

<h3>Introduction</h3> NeoCast<sup>TM</sup> is a solvent-free, shear-responsive, <i>in-situ</i> curing biomaterial designed for embolization applications where complete casting and occlusion of micron-sized vessel branches is desired. <h3>Aim of Study</h3> Assess the preclinical performance of NeoCast with respect to distal penetration, radiopacity, and biological (vascular and brain tissue) safety response. <h3>Methods</h3> NeoCast embolization and safety performance was evaluated in a swine kidney model at 7, 30, and 90 days (n=8 injections/timepoint). Onyx-18® (Medtronic) and polyvinyl alcohol particles (PVA, Cook 90-180 micron) were used as controls (n=6 injections/timepoint). Distal penetration and radiopacity were assessed via micro-computed tomography imaging of explanted kidneys. Histopathology consisted of assessing fibrosis, necrosis, and inflammatory local vascular responses. Neurotoxicity was assessed at 7 (n=4) and 90 (n=8) days by injecting NeoCast directly into rabbit brain parenchyma allowing <i>in-situ</i> cure. High density polyethylene rods were used as negative controls. Neuropathological evaluation consisted of characterizing inflammatory response and necrosis. <h3>Results</h3> NeoCast occluded ~5.2x more vessel branches compared to Onyx-18 (p=0.006). Histologically, NeoCast was present more frequently in smaller arteries (&lt;200µm) compared to PVA (64% vs 15%, p&lt;0.001). Radiographically, NeoCast embolic casts exhibited a homogeneous appearance with minimal artifact. NeoCast local vascular response was similar to Onyx-18 and PVA: inflammation was mild and stable throughout 90 days, indicative of a non-degrading, bioinert material. NeoCast elicited a benign neurotoxic response with minimal inflammation and no necrosis. <h3>Conclusion</h3> NeoCast exhibits superior distal penetration and radiopacity compared to commercially available embolics and elicits safe vascular and brain tissue responses in animal models. Future studies evaluating NeoCast in human subjects are warranted. <h3>Disclosure of Interest</h3> no.

Authors

Institutions

Publication Details

Journal
Abstracts
Published
2024-09-01
DOI
https://doi.org/10.1136/jnis-2024-esmint.15
Primary Topic
Radiation Dose and Imaging
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

O15 Assessment of distal penetration, radiopacity, and biological safety response of NeoCast(TM), a unique solvent-free, non-adhesive embolic material

Quynh P. Pham, Chander Sadasivan, David J. Fiorella, Jeffrey Groom et al.
Abstracts
Radiation Dose and Imaging
article

O15 Assessment of distal penetration, radiopacity, and biological safety response of NeoCast(TM), a unique solvent-free, non-adhesive embolic material

Quynh P. Pham, Chander Sadasivan, David J. Fiorella, Jeffrey Groom, Adam S Arthur
article en

Abstract

<h3>Introduction</h3> NeoCast<sup>TM</sup> is a solvent-free, shear-responsive, <i>in-situ</i> curing biomaterial designed for embolization applications where complete casting and occlusion of micron-sized vessel branches is desired. <h3>Aim of Study</h3> Assess the preclinical performance of NeoCast with respect to distal penetration, radiopacity, and biological (vascular and brain tissue) safety response. <h3>Methods</h3> NeoCast embolization and safety performance was evaluated in a swine kidney model at 7, 30, and 90 days (n=8 injections/timepoint). Onyx-18® (Medtronic) and polyvinyl alcohol particles (PVA, Cook 90-180 micron) were used as controls (n=6 injections/timepoint). Distal penetration and radiopacity were assessed via micro-computed tomography imaging of explanted kidneys. Histopathology consisted of assessing fibrosis, necrosis, and inflammatory local vascular responses. Neurotoxicity was assessed at 7 (n=4) and 90 (n=8) days by injecting NeoCast directly into rabbit brain parenchyma allowing <i>in-situ</i> cure. High density polyethylene rods were used as negative controls. Neuropathological evaluation consisted of characterizing inflammatory response and necrosis. <h3>Results</h3> NeoCast occluded ~5.2x more vessel branches compared to Onyx-18 (p=0.006). Histologically, NeoCast was present more frequently in smaller arteries (&lt;200µm) compared to PVA (64% vs 15%, p&lt;0.001). Radiographically, NeoCast embolic casts exhibited a homogeneous appearance with minimal artifact. NeoCast local vascular response was similar to Onyx-18 and PVA: inflammation was mild and stable throughout 90 days, indicative of a non-degrading, bioinert material. NeoCast elicited a benign neurotoxic response with minimal inflammation and no necrosis. <h3>Conclusion</h3> NeoCast exhibits superior distal penetration and radiopacity compared to commercially available embolics and elicits safe vascular and brain tissue responses in animal models. Future studies evaluating NeoCast in human subjects are warranted. <h3>Disclosure of Interest</h3> no.

Abstracts
Arsenal Medical (United States) (US), Semmes Murphey Foundation (US), Stony Brook University (US), University of Tennessee at Knoxville (US)
Openalex Percentile: Top 75%
Radiation Dose and Imaging
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.